6
total announcements
SYMBIOTEC.NS · 15 min delayed
Key Stats · Yahoo Finance · as of 06 Nov 2026
P/E (TTM)
86.9
P/E (Forward)
44.3
EPS (TTM)
₹14.63
52W Low
₹934.20
52W High
₹1,309.90
Dividend Yield
0.00%
Price / Book
6.9
Debt / Equity
34.0
Revenue (TTM)
₹884 Cr
Gross Margin
61.26%
Operating Margin
10.71%
Symbiotec Pharmalab Ltd
Symbiotec Pharmalab Ltd has intimated the BSE about the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information framed under Regulation 8(1) of SEBI PIT Regulations, which will come into effect from December 15, 2025.
Symbiotec Pharmalab Ltd
Symbiotec Pharmalab Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 from Mirae Asset Mutual Fund.
Symbiotec Pharmalab Ltd
Symbiotec Pharmalab Ltd has closed its trading window for the quarter ended June 30, 2026, in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, and will remain closed until 48 hours after the declaration of unaudited Financial Results.
Symbiotec Pharmalab Ltd
Symbiotec Pharmalab Ltd has submitted the Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information as required by SEBI (Prohibition of Insider Trading) Regulations, 2015.
Symbiotec Pharmalab Ltd
Symbiotec Pharmalab Ltd has disclosed the authorized personnel for determining materiality of events or information under Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Symbiotec Pharmalab Ltd
Symbiotec Pharmalab Ltd's equity shares have been listed and admitted to trading on the BSE, effective from September 01, 2026, with scrip code 544889.